A Study of Remternetug (LY3372993) in Healthy Participants

NCT ID: NCT07056309

Last Updated: 2025-10-14

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-24
• Study Completion Date: 2025-12-31

Brief Summary

The main purpose of this study is to evaluate to different formulations of remternetug after single subcutaneous (SC) administration with either an autoinjector (AI) or a prefilled syringe (PFS). The study will look at the amount of remternetug that gets into the bloodstream and how long it takes the body to get rid of the remternetug when given as two different formulations.

Participation in the study will last approximately 155 days.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Remternetug (Test)

Remternetug administered subcutaneously (SC) via autoinjector (AI)

Group Type: EXPERIMENTAL

Remternetug (Test)

Intervention Type: DRUG

Administered SC

Remternetug (Reference)

Remternetug administered SC via prefilled syringe.

Group Type: EXPERIMENTAL

Remternetug (Reference)

Intervention Type: DRUG

Administered SC

Interventions

Remternetug (Test)

Administered SC

Intervention Type: DRUG

Remternetug (Reference)

Administered SC

Intervention Type: DRUG

Other Intervention Names

LY3372993; LY3372993

Eligibility Criteria

Inclusion Criteria

• Are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring.
• Have a body mass index within the range of 18.0 to 34.0 kilograms per meter squared (kg/m2) (inclusive).

Exclusion Criteria

• Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs or of constituting a risk when taking the study drug or of interfering with the interpretation of data.
• Have evidence of significant active neuropsychiatric disease, as determined by the investigator.
• Have a personal or family history of early onset AD (AD diagnosed prior to 65 years of age).
• Contraindication to MRI, including claustrophobia that cannot be managed with low-dose sedatives or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemakers.
• Intend to use over-the-counter or prescription medication, including herbal medications and traditional medications, with the exception of vitamin/mineral supplements, any hormone replacement therapy, and/or thyroid replacement therapy, within 7 days prior to dosing and for the duration of the study.
• Have a brain MRI that demonstrates any clinically significant findings that, in the opinion of the investigator, may impact the participant's ability to safely participate in the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Eli Lilly and Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

Fortrea Clinical Research Unit

Daytona Beach, Florida, United States

QPS Missouri

Springfield, Missouri, United States

Fortrea Clinical Research Unit

Dallas, Texas, United States

Countries

United States

Other Identifiers

J1G-MC-LAKG

Identifier Type: OTHER

Identifier Source: secondary_id

18471

Identifier Type: -

Identifier Source: org_study_id